Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 388-396

  Gelderblom, H ^a   Blay, J Y ^b   Seddon, B M ^c   Leahy, M ^d   Ray Coquard, I ^b   Sleijfer, S ^e   Kerst, J M ^f   Rutkowski, P ^g   Bauer, S ^h   Ouali, M ⁱ   Marreaud, S ⁱ   Van Der Straaten, R J H M ^a   Guchelaar, H J ^a   Weitman, S D ^j   Hogendoorn, P C W ^a   Hohenberger, P ^k  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ EORTC DATA CENTER   (Belgium)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Brostallicin; Doxorubicin; GST; Randomised phase II study; Soft tissue sarcoma

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BROSTALLICIN; DOXORUBICIN; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IFOSFAMIDE; TROFOSFAMIDE;

ADULT; ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT DISORDER; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTRANSAMINASEMIA; LOCAL THERAPY; MAJOR CLINICAL STUDY; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARALLEL DESIGN; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; SYSTOLIC DYSFUNCTION; VOMITING;

EID: 84891827931     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.002     Document Type: Article

References (14)

1. The ESMO/European Sarcoma Networking Group Soft tissue and visceral sarcoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl. 7 2012 S92 S99
2. P. Lorigan, J. Verweij, and Z. Papai et al. Phase III trial of 2 investigational schedules of ifosfamide compared with standard-dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma, a European Organisation of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study J Clin Oncol 25 2007 3144 3150
3. I. Judson, J. Verweij, and H. Gelderblom et al. Results of a randomized phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group ESMO 2012 LBA07
4. G.D. Demetri, S.P. Chawla, and M. von Mehren et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of 2 different schedules J Clin Oncol 27 2009 4188 4196
5. W.T.A. Van der Graaf, J.Y. Blay, and S.P. Chawla et al. Pazopanib for metastatic soft tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled fase 3 trial Lancet 379 2012 1879 1886
6. M. Broggini, S. Marchini, and E. Fontana et al. Brostallicin: a new concept in minor groove DNA binder development Anticancer Drugs 15 2004 1 6
7. C. Geroni, S. Marchini, and P. Cozzi et al. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione Cancer Res 15 2002 2332 2336
8. M. Leahy, I. Ray-Coquard, and J. Verweij et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma, a phase II study from the European Organisation of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Eur J Cancer 43 2007 208 215
9. M. Van Glabbeke, J. Verweij, and I. Judson et al. Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas Eur J Cancer 38 2002 543 549
10. J. Verweij, S.M. Lee, and W. Ruka et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line therapy in patients with locally advanced and metastatic soft tissue sarcoma in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol 18 2000 2081 2086
11. N. Penel, M. Van Glabbeke, and S. Mathoulin-Pelissier et al. Performance status is the most powerful risk factor for early death amongst patients with soft tissue sarcoma: a study of the European Organisation of Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and the French Sarcoma Group (FSG) study Br J Cancer 104 2011 1544 1550
12. C. Sweeney, C.B. Ambrosone, and L. Joseph et al. Association between a glutathione S-transferase A1 promotor polymorphism and survival after breast cancer treatment Int J Cancer 103 2003 810 814
13. A.V. Khrunin, A. Moisseev, V. Gorbunova, and S. Limborska Genetic polymorphisms and the efficacy and toxicity of cisplatin based chemotherapy in ovarian cancer patients Pharmacogenomics J 10 2010 54 61
14. H.A. Dirven, B. van Ommen, and P. van Bladeren Involvement of human glutathione S-transferase isoenzymes in the conjugation cyclophosphamide metabolites with glutathione Cancer Res 54 1994 2615 2620